Failure to validate toxicity and outcome biomarkers from the FFCD 2000-05 trial in the MRC CR08 FOCUS trial

Journal of Clinical Oncology

Volumn 29, Issue 12, 2011, Pages

  Richman, Susan D ^a   Barrett, Jennifer H ^a   Seymour, Matthew T ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; CHLOROFORM; EOSIN; FLUOROURACIL; FOLINIC ACID; HEMATOXYLIN; IRINOTECAN; ISOPENTYL ALCOHOL; OXALIPLATIN; PHENOL; PROTEINASE K;

BLOOD SAMPLING; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DNA EXTRACTION; GENETIC POLYMORPHISM; GENOTYPE; GERMLINE MICRONUCLEUS; HUMAN; LETTER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMALL INTESTINE MUCOSA;

5' UNTRANSLATED REGIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENE FREQUENCY; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79955037979     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9556     Document Type: Letter

References (2)

1. Boige V, Mendiboure J, Pignon JP, et al: Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 28:2556-2564, 2010
2. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007 (Pubitemid 47042894)